Johns Hopkins Medicine: Novel Drug Combination Shows Promise for Advanced HER2-Negative Breast Cancer
February 15, 2024
February 15, 2024
BALTIMORE, Maryland, Feb. 15 (TNSres) -- Johns Hopkins Medicine issued the following news release:
A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center. The treatment included a histone deacetylase (HDAC) inhibitor -- a drug that causes a chemical change to stop tumor cells from dividing -- with two types of immunotherapy known a . . .
A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center. The treatment included a histone deacetylase (HDAC) inhibitor -- a drug that causes a chemical change to stop tumor cells from dividing -- with two types of immunotherapy known a . . .